In March, Sen. Susan Collins, R-Maine, introduced the Patient Right to Know Drug Prices Act. Backed by a bipartisan group of lawmakers, the bill bans the “gag clauses” that prevent pharmacies from informing consumers whether they could spend less on their medication by paying the full price for an identical product produced by a different manufacturer.
Read More
Sen. Bill Cassidy (R-LA), shared Dr. Levin’s, ATAP President, op-ed on his social media channels highlighting the support ATAP has given to the PBM issue at the federal level.
Read MoreDr. Robert Levin offers insight into pharmacy benefit managers and their lack of transparency.
Read MoreAmericans spend more per capita on prescription drugs than any other high-income country in the world. Many states have wrestled with the rising costs of these medications, particularly in Florida.
Read MoreState efforts to address harmful PBM practices are continuing to gain momentum across the country, with numerous states considering PBM-related legislation this session. Here are some recent state advocacy highlights:
Read MoreATAP is once again pleased to report that Colorado passed a bill (HB 1284) last week aimed at regulating PBMs, the latest in the growing movement sweeping across the nation.
Read MoreATAP is pleased to report that an Arizona bill aimed at regulating PBMs was passed through the legislature unanimously, and was signed into law by Governor Ducey on April 5.
Read MoreATAP is pleased to report that yet another state has passed PBM legislation. Last week, the Kentucky legislature unanimously passed HB 463. The bill now heads to Governor Bevin for his signature.
Read MoreATAP is pleased to report that five states have now passed legislation this year aimed at regulating PBMs in yet another sign that our coalition’s core message and extensive advocacy outreach is continuing to resonate not only with state lawmakers, but also with the general public.
Read More